Susan E Creary1, Deena J Chisolm1, Terah L Koch1, Victoria A Zigmont2, Bo Lu3, Sarah H O'Brien1. 1. Division of Pediatric Hematology and Oncology, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio. 2. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio. 3. Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, Ohio.
Abstract
BACKGROUND: Expert guidelines recommend that hydroxyurea (HU) be offered to all children with hemoglobin SS and Sβ(0) sickle cell disease (SCD) and be considered for children with clinically severe hemoglobin SC or Sβ(+) . This study aims to determine the rate of HU use in hospitalized children, if HU is differentially used in children with clinically severe SCD, and if HU users have shorter length of stay (LOS), fewer intensive care unit (ICU) admissions, and fewer inpatient transfusions compared to nonusers. PROCEDURE: Using the Pediatric Health Information System, we performed a retrospective analysis of children ages 2-18 years with SCD discharged between January 1, 2011 and September 30, 2014. We defined patients as having clinically severe SCD if they had a recent ICU admission or ≥3 admissions in the preceding year. RESULTS: Of the 2,665 unique children identified, approximately 80% had an inpatient code indicating HU use. Significantly more (p < 0.001) nonusers (30.1%) had a recent ICU admission compared to HU users (18.7%). More nonusers (33.9%) had a history of ≥3 admissions compared to HU users (21.5%) (p < 0.001). After applying propensity score weighting, the groups did not differ in their LOS, prevalence of ICU admissions, or prevalence of transfusions. CONCLUSIONS: HU use is high among hospitalized children with SCD. However, HU is not utilized by many children with clinically severe SCD. These results support that HU be considered in children with SCD to prevent hospitalization rather than as a treatment to improve hospitalization outcomes.
BACKGROUND: Expert guidelines recommend that hydroxyurea (HU) be offered to all children with hemoglobin SS and Sβ(0) sickle cell disease (SCD) and be considered for children with clinically severe hemoglobin SC or Sβ(+) . This study aims to determine the rate of HU use in hospitalized children, if HU is differentially used in children with clinically severe SCD, and if HU users have shorter length of stay (LOS), fewer intensive care unit (ICU) admissions, and fewer inpatient transfusions compared to nonusers. PROCEDURE: Using the Pediatric Health Information System, we performed a retrospective analysis of children ages 2-18 years with SCD discharged between January 1, 2011 and September 30, 2014. We defined patients as having clinically severe SCD if they had a recent ICU admission or ≥3 admissions in the preceding year. RESULTS: Of the 2,665 unique children identified, approximately 80% had an inpatient code indicating HU use. Significantly more (p < 0.001) nonusers (30.1%) had a recent ICU admission compared to HU users (18.7%). More nonusers (33.9%) had a history of ≥3 admissions compared to HU users (21.5%) (p < 0.001). After applying propensity score weighting, the groups did not differ in their LOS, prevalence of ICU admissions, or prevalence of transfusions. CONCLUSIONS:HU use is high among hospitalized children with SCD. However, HU is not utilized by many children with clinically severe SCD. These results support that HU be considered in children with SCD to prevent hospitalization rather than as a treatment to improve hospitalization outcomes.
Authors: Winfred C Wang; Suzette O Oyeku; Zhaoyu Luo; Sheree L Boulet; Scott T Miller; James F Casella; Billie Fish; Bruce W Thompson; Scott D Grosse Journal: Pediatrics Date: 2013-09-02 Impact factor: 7.124
Authors: Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson Journal: Lancet Date: 2011-05-14 Impact factor: 79.321
Authors: Clarisse Lopes de Castro Lobo; Jorge F C Pinto; Emilia M Nascimento; Patricia G Moura; Gilberto P Cardoso; Jane S Hankins Journal: Br J Haematol Date: 2013-04-17 Impact factor: 6.998
Authors: Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah Journal: JAMA Date: 2014-09-10 Impact factor: 56.272
Authors: Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski Journal: Clin Pediatr (Phila) Date: 2019-05-21 Impact factor: 1.168
Authors: Susan E Creary; Avani C Modi; Joseph R Stanek; Deena J Chisolm; Sarah H O'Brien; Cara Nwankwo; Lori E Crosby Journal: J Pediatr Psychol Date: 2019-11-01
Authors: David G Bundy; Troy E Richardson; Matthew Hall; Jean L Raphael; David C Brousseau; Staci D Arnold; Ram V Kalpatthi; Angela M Ellison; Suzette O Oyeku; Samir S Shah Journal: JAMA Pediatr Date: 2017-11-01 Impact factor: 16.193
Authors: Lydia H Pecker; Sarah Kappa; Adam Greenfest; Deepika S Darbari; Robert Sheppard Nickel Journal: J Pediatr Date: 2018-06-29 Impact factor: 4.406
Authors: Susan E Creary; Sarah H O'Brien; Joseph Stanek; Jane S Hankins; Amy Garee; Kyle R Ball; Tina M Andrews; Deena J Chisolm Journal: Pediatr Qual Saf Date: 2017-05-25